RAISE: TAK-755 in Sickle Cell Disease

Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing TAK-755 Arm with Placebo Arm (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Day 28 and Number of Participants Who Developed Positive Binding and Inhibitory Anti-ADAMTS13 Antibodies at Day 28. Started Oct 2019; status: completed.